Canbey Ceren, Şen Sena, Karabulut Senem, Özcan Tevhide Bilgen, Paşaoğlu Esra, Altun Eren, Kuzan Taha Yusuf, Ezberci Fikret
Department of Medicine Pathology, Bagcilar Research and Training Hospital, Istanbul, Türkiye.
Department of Molecular Oncology, Hamidiye Health Sciences Institute, University of Health Sciences, Istanbul, Türkiye.
Cytojournal. 2025 May 6;22:47. doi: 10.25259/Cytojournal_2_2025. eCollection 2025.
Pancreatic cancer is the cancer type with the highest mortality rate worldwide, and despite advances in treatment, molecular biomarkers are needed for both early diagnosis for developing targeted therapies and improving survival rates in this challenging malignancy. In our study, the contributions of programmed death-ligand 1 (PD-L1) expression to the determination of pancreatic cancer subtypes and patient prognosis and its impact on survival were investigated.
Paraffin-embedded tissues from 92 patients diagnosed with pancreatic cancer were included in this study. Tumor-infiltrating lymphocytes (TILs) and lymphocytes in the stromal area within the tumor borders were scored as stromal TILs; lymphocytes in tumor islands were scored as intratumoral TILs. Staining in each area was scored as a percentage, and staining with a score of 5 or more in tumor and immune cells for PD-L1 was scored as positive.
After staining, a score of 5 or more with tPD-L1 staining was used to identify one patient as having micropapillary adenocarcinoma, three patients as having ductal adenocarcinoma, and four patients as having signet ring cell carcinoma. When the clinical parameters and outcomes were compared, a statistically significant difference was found between the histopathologic type of signet ring cell carcinoma and poor differentiation and positivity of PD-L1 expression ( < 0.05). Survival was significantly influenced by tumor location, histopathological subtype, degree of differentiation, PD-L1 expression, and tumor size, with tumor size being the most critical factor ( < 0.05).
Our findings suggest that PD-L1 positivity is notably prevalent in signet ring cell carcinoma of the pancreas and is strongly associated with poor survival outcomes. Given these results, further studies with larger patient cohorts are warranted to validate these observations and explore potential therapeutic implications.
胰腺癌是全球死亡率最高的癌症类型,尽管治疗方面取得了进展,但仍需要分子生物标志物用于早期诊断以开发靶向治疗,并改善这种具有挑战性的恶性肿瘤的生存率。在我们的研究中,探讨了程序性死亡配体1(PD-L1)表达对胰腺癌亚型判定和患者预后的贡献及其对生存的影响。
本研究纳入了92例经诊断为胰腺癌患者的石蜡包埋组织。肿瘤浸润淋巴细胞(TILs)以及肿瘤边界内基质区域的淋巴细胞被计为基质TILs;肿瘤岛中的淋巴细胞被计为瘤内TILs。每个区域的染色按百分比评分,PD-L1在肿瘤细胞和免疫细胞中染色评分为5分及以上记为阳性。
染色后,tPD-L1染色评分为5分及以上的患者中,1例为微乳头腺癌,3例为导管腺癌,4例为印戒细胞癌。比较临床参数和结果时,发现印戒细胞癌的组织病理学类型与低分化以及PD-L1表达阳性之间存在统计学显著差异(<0.05)。生存受到肿瘤位置、组织病理学亚型、分化程度、PD-L1表达和肿瘤大小的显著影响,其中肿瘤大小是最关键因素(<0.05)。
我们的研究结果表明,PD-L1阳性在胰腺印戒细胞癌中显著普遍,且与较差的生存结果密切相关。鉴于这些结果,有必要对更大患者队列进行进一步研究,以验证这些观察结果并探索潜在的治疗意义。